US Patent

US10137131 — Pharmaceutical compositions comprising meloxicam

Method of Use · Assigned to Axsome Therapeutics Inc · Expires 2036-04-11 · 10y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions that combine a triptan or NSAID, such as meloxicam, with a cyclodextrin and/or a carbonate or bicarbonate.

USPTO Abstract

Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

Drugs covered by this patent

Mobic (MELOXICAM) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1719`	—	Mobic

Patent Metadata

Patent number: US10137131
Jurisdiction: US
Classification: Method of Use
Expires: 2036-04-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Axsome Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.